• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor® Announces CEO Transition

    4/25/25 6:07:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email

    Board initiates search process to identify next CEO

    RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor.

    Avantor. Setting science in motion to create a better world. (PRNewsfoto/Avantor)

    The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led by an executive search firm. The Board plans to move through the process expeditiously.

    "On behalf of the Board, I thank Michael for over a decade of dedicated service and leadership to Avantor," said Jonathan Peacock, Chairman of the Board of Directors. "Guided by a deep commitment to the Company and our mission, Michael has built Avantor into a global player in the life sciences tools space."

    Mr. Peacock continued, "We intend to identify a strong successor with a track record of delivering growth and value creation. The Avantor platform is durable and resilient, with differentiated capabilities, a broad and expanding portfolio, and a global customer base and supply chain."

    "It has been an honor to lead Avantor and work alongside our team to transform the Company into a leading life science tools company and global provider of mission-critical products for life sciences and technologies customers," said Michael Stubblefield. "Avantor has a unique and differentiated role in enabling our customers to serve patients, and with the support of the thousands of incredible associates around the world, I know we have a bright future ahead. I look forward to continuing to work with the Board and leadership team while the Board identifies the right leader for the Company's next chapter."

    Given his extensive history with the company, Mr. Stubblefield will be retained by the Board until February 2026 to provide ad hoc input if and as needed to ensure the new CEO settles in quickly.

    First Quarter 2025 Results and Conference Call

    In a separate press release issued today, Avantor announced its financial results for the first quarter of 2025. The Company will host a conference call to discuss its results today, April 25, 2025, at 8:00 a.m. Eastern Time. The live webcast and presentation, as well as a replay, will be available on the investor section of Avantor's website. 

    About Avantor

    Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development, and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter), and Facebook.

    Forward-Looking and Cautionary Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, including our cost transformation initiative, objectives, future performance and business. These statements may be preceded by, followed by or include the words "aim," "anticipate," "assumption," "believe," "continue," "estimate," "expect," "forecast," "goal," "guidance," "intend," "likely," "long-term," "near-term," "objective," "opportunity," "outlook," "plan," "potential," "project," "projection," "prospects," "seek," "target," "trend," "can," "could," "may," "should," "would," "will," the negatives thereof and other words and terms of similar meaning.

    Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in "Risk Factors" in our most recent Annual Report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.

    All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.

    Investor Relations Contact

    Allison Hosak

    Senior Vice President, Global Communications

    Avantor

    908-329-7281

    [email protected]

    Global Media Contact

    Eric Van Zanten

    Head of External Communications

    Avantor

    610-529-6219

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-announces-ceo-transition-302438056.html

    SOURCE Avantor and Financial News

    Get the next $AVTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    8/28/2024$30.00Overweight
    Wells Fargo
    7/10/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    1/4/2024$19.50 → $26.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Summe Gregory L bought $375,000 worth of shares (30,000 units at $12.50) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/27/25 4:58:03 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Summe Gregory L bought $253,000 worth of shares (20,000 units at $12.65) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/22/25 5:37:34 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Summe Gregory L bought $300,000 worth of shares (25,000 units at $12.00) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/9/25 4:51:58 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    SEC Filings

    See more
    • SEC Form SD filed by Avantor Inc.

      SD - Avantor, Inc. (0001722482) (Filer)

      5/30/25 4:37:48 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Avantor, Inc. (0001722482) (Filer)

      5/12/25 5:16:45 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Avantor, Inc. (0001722482) (Filer)

      4/28/25 8:29:56 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avantor® to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

      RADNOR, Pa., May 16, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Brent Jones, Executive Vice President and Chief Financial Officer, will be participating in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 20, 2025 at approximately 8:00 a.m. Eastern Time.  To view the presentation slides and to hear a live audio webcast of the session, visit Events & Presentations in the I

      5/16/25 8:30:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® to Participate in Bank of America Securities 2025 Health Care Conference

      RADNOR, Pa., May 2, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at approximately 10:00 a.m. Pacific Time.  To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscience

      5/2/25 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® Announces CEO Transition

      Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor. The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led

      4/25/25 6:07:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials